Dr. Bosse on Rationale Behind Study of VEGF Plus Radium-223 in RCC

Dominick Bosse, MD
Published: Thursday, Sep 21, 2017



Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses the rationale behind combining VEGF-targeted therapies and radium-223 dichloride (Xofigo) in metastatic renal cell carcinoma (mRCC).

In a study of patients with mRCC with bone metastases, pazopanib (Votrient) or sorafenib (Nexavar) was combined with radium-223. Primary endpoints were safety, efficacy and bone turnover markers.
 


Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses the rationale behind combining VEGF-targeted therapies and radium-223 dichloride (Xofigo) in metastatic renal cell carcinoma (mRCC).

In a study of patients with mRCC with bone metastases, pazopanib (Votrient) or sorafenib (Nexavar) was combined with radium-223. Primary endpoints were safety, efficacy and bone turnover markers.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x